Ohnishi Shunsuke, Nagaya Noritoshi
Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Suita, Osaka, Japan.
Int J Chron Obstruct Pulmon Dis. 2008;3(4):509-14. doi: 10.2147/copd.s1092.
COPD is a major cause of chronic morbidity and mortality worldwide, and there is a need to develop more effective therapeutic strategies to replace specialized treatment such as lung transplantation. Recent studies suggest that recognition of apoptotic lung epithelial or endothelial cells may result in growth factors to stimulate cell replacement, and defects in these processes may contribute to the pathogenesis of COPD. Furthermore, recent animal and human studies have revealed that tissue-specific stem cells and bone marrow-derived cells contribute to lung tissue regeneration and protection, and thus administration of exogenous stem/progenitor cells or humoral factors responsible for activation of endogenous stem/progenitor cells may be a potent next-generation therapy for COPD.
慢性阻塞性肺疾病(COPD)是全球慢性发病和死亡的主要原因,因此需要开发更有效的治疗策略来替代诸如肺移植等专科治疗。最近的研究表明,识别凋亡的肺上皮或内皮细胞可能会产生生长因子以刺激细胞替代,而这些过程中的缺陷可能会导致COPD的发病机制。此外,最近的动物和人体研究表明,组织特异性干细胞和骨髓来源的细胞有助于肺组织的再生和保护,因此给予外源性干细胞/祖细胞或负责激活内源性干细胞/祖细胞的体液因子可能是COPD的一种有效的下一代治疗方法。